Article
Boston--The fact that prostate cancer recurrence can be indolent may actually be detrimental to the development of drugs for patients in whom recurrence is life-threatening.
Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
EV/pembrolizumab continues to show OS, PFS benefit vs chemotherapy in la/mUC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status
Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment